Welcome to our dedicated page for Y-Mabs Therapeutics news (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-Mabs Therapeutics stock.
Y-mAbs Therapeutics, Inc. (YMAB) is a commercial-stage biopharmaceutical leader pioneering antibody-based therapies and radioimmunotherapy for pediatric and adult cancers. This page provides investors and medical professionals with comprehensive access to Y-mAbs' official news, including FDA regulatory updates, clinical trial results, and strategic partnership announcements.
As the developer of DANYELZA – an FDA-approved treatment for high-risk neuroblastoma – Y-mAbs demonstrates ongoing innovation through its SADA PRIT platform and bispecific antibody research. Our curated news collection enables stakeholders to track the company's progress in advancing precision oncology treatments while maintaining compliance with rigorous clinical standards.
Key updates include press releases on product commercialization milestones, peer-reviewed study publications, and developments in the company's pipeline targeting GD2-expressing tumors. All content is sourced directly from Y-mAbs Therapeutics and verified financial disclosures to ensure reliability.
Bookmark this page for real-time updates on YMAB's scientific advancements and market-moving developments. Investors can leverage this resource to monitor the company's progress in bringing novel radioimmunotherapies through clinical trials to commercialization.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based cancer treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Michael Rossi, President and CEO, will deliver a presentation on January 15, 2025, at 5:15 p.m. PT in San Francisco.
The presentation will be accessible via live webcast through the Events section of Y-mAbs' investor relations website at ir.ymabs.com. The recording will remain available for replay for 30 days following the event.
Y-mAbs Therapeutics (NASDAQ: YMAB) presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also presented details of its ongoing Phase 1 Trial 1201, evaluating CD38-SADA PRIT with Lu177-DOTA in adults with relapsed or refractory NHL. The trial consists of two parts: Part A focuses on dose escalation of CD38-SADA protein, while Part B aims to establish the optimal therapeutic dose of Lu177-DOTA. Both parts follow a 3+3 trial design with 4 planned dose levels.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based cancer treatments, has announced its participation in Citi's 2024 Global Healthcare Conference. The company's management team will conduct one-on-one meetings at the conference on December 4, 2024 in Miami, FL. Interested parties can schedule meetings through their Citi representative or by contacting cdu@ymabs.com.
Y-mAbs Therapeutics reported Q3 2024 financial results with total DANYELZA net product revenues of $18.5 million, marking a 10% decline from Q3 2023. The company entered into an exclusive license agreement with Nobelpharma for DANYELZA in Japan, securing a $2.0 million upfront payment. Key developments include the extension of DANYELZA's U.S. patent through February 2034 and market expansion into Turkey. Net loss for Q3 2024 was $7.0 million ($0.16 per share), compared to $7.7 million in Q3 2023. The company maintains its 2024 guidance with expected total net revenues between $87-95 million and cash position supporting operations into 2027.
Y-mAbs Therapeutics (NASDAQ: YMAB) and Nobelpharma have signed an exclusive license and distribution agreement for DANYELZA® in Japan. The agreement covers the development and commercialization of DANYELZA for treating relapsed/refractory high-risk neuroblastoma and potentially relapsed osteosarcoma. Y-mAbs will receive a $2.0 million upfront payment and could earn up to $31.0 million in milestone payments, plus profit sharing on commercial sales. Nobelpharma will handle regulatory submissions, marketing, sales, and distribution in Japan.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based cancer treatments, has scheduled its third quarter 2024 financial results announcement. The company will release results before market open on November 8, 2024, followed by a conference call and webcast at 8:00 a.m. ET. Domestic investors can dial (877) 407-0792, while international investors can use (201) 689-8263 to participate.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences in October 2024:
1. Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 9:30 a.m. ET
- Location: New York, NY
- Panel: "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes"
2. BMO Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 3:00 p.m. ET
- Location: New York, NY
- Fireside chat: "Shifting the Antibody Paradigm"
These conferences provide Y-mAbs with opportunities to showcase its developments in cancer therapeutics and engage with investors.
Y-mAbs Therapeutics (Nasdaq: YMAB) presented new clinical and preclinical data on naxitamab and GD2-SADA for neuroblastoma treatment at the AACR Special Conference. Key findings include:
1. Naxitamab with GM-CSF achieved a 63% disease control rate in refractory/relapsed high-risk neuroblastoma patients.
2. GD2-SADA demonstrated high-affinity binding to Tb-DOTA, supporting its potential in pre-targeted radiotherapy (PRIT).
3. Ongoing clinical trials: Trial 201 for naxitamab, Trial 1001 for GD2-SADA PRIT in adolescents and adults, and planned Trial 1002 for pediatric patients.
These results highlight Y-mAbs' progress in developing innovative treatments for high-risk neuroblastoma, the most common extracranial solid tumor in children.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences. Michael Rossi, President and CEO, will represent the company at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 1:50 p.m. ET in New York, NY.
2. Cantor Global Healthcare Conference on September 17, 2024, at 3:40 p.m. ET in New York, NY.
Both events will feature fireside chats and investor 1x1 meetings. Live webcasts of the fireside chats and related materials will be available on Y-mAbs' investor relations website under the Presentations section, with archives accessible for at least 30 days.
Y-mAbs Therapeutics (YMAB) reported Q2 2024 financial results and corporate developments. Highlights include:
- DANYELZA net product revenues of $22.8 million, up 10% YoY
- Geographic expansion with new revenues from Brazil and Mexico
- Phase 1 GD2-SADA Trial Part A expected completion in Q4 2024
- Appointed new CFO and Chief Development Officer
- Cash and cash equivalents of $77.8 million as of June 30, 2024
- Updated Full Year 2024 Total Net Revenue guidance
The company reported a net loss of $9.2 million ($0.21 per share) for Q2 2024, compared to a $6.3 million loss ($0.14 per share) in Q2 2023. Management expects current cash to support operations into 2027.
